2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (E)-octadec-9-enoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (E)-octadec-9-enoate
• 化学式: C₃₂H₆₀O₁₀
• 分子量: 604.8
• InChiKey: HDTIFOGXOGLRCB-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  42
• 可旋转键数：
  31
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• APPARATUS AND METHODS FOR HYGIENE TESTING A MEDICAL DEVICE
  申请人：Novaflux, Inc.

  公开号：EP3504531A1

  公开（公告）日：2019-07-03
• IMMEDIATE RELEASE CLINDAMYCIN DELIVERY COMPOSITION AND FORMULATION
  申请人：Iono Pharma, LLC

  公开号：US20180256746A1

  公开（公告）日：2018-09-13

  This invention relates to a pharmaceutical composition made of a clindamycin salt complexed with strongly acidic non-spherical resin particles, wherein predominantly all of the resin particles are less than 75 microns in diameter, to form clindamycin-resin complex, wherein in the clindamycin-resin complex provides for immediate release of the clindamycin in a target environment and at least one non-ionic excipient. In one embodiment, the inventive subject matter is an oral liquid pharmaceutical formulation made of a complex of clindamycin hydrochloride, a fractionated resin and excipients to stabilize the complex. The pharmaceutical formulation remains stable in deionized water until the dosage form reaches an ion-rich environment (stomach or intestine), there which the active ingredient clindamycin hydrochloride is released.
• [EN] APPARATUS AND METHODS FOR HYGIENE TESTING A MEDICAL DEVICE<br/>[FR] APPAREILS ET PROCÉDÉS DESTINÉS À TESTER L'HYGIÈNE D'UN DISPOSITIF MÉDICAL
  申请人：NOVAFLUX INC

  公开号：WO2018039443A1

  公开（公告）日：2018-03-01

  Provided among other things is a sampling system for determining an amount or type of contamination a narrow, elongated passageway in a medical device, said sampling system comprising: (a) a fluid supply system that supplies to said passageway a sampling liquid for flowing through said passageway and a gas for flowing through said passageway; and (b) a receiving container that receives liquid from said passageway, wherein said sampling liquid is sterile, wherein said sampling liquid is configured to allow recovery of viable pathogens from the passageway, and wherein said sampling liquid comprises an amount and selection of surfactant effective to enhance the dislodgement of Enterococcus faecalis and Pseudomonas aeruginosa bacteria from the narrow passageways.